Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11454847 | 0.93 | ALDH1A1 (0.34) | OPRL1ALDH1A1HPGDAPOBEC3G | |
| SCHEMBL27811174 | 0.91 | ALDH1A1 (0.33) | OPRL1ALDH1A1HPGDAPOBEC3GOPRM1 | |
| SCHEMBL7369318 | 0.91 | CYP2D6 (0.31) | OPRL1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL2910041 | 0.86 | L3MBTL3 (0.31) | — | |
| SCHEMBL7008001 | 0.84 | — | — | |
| SCHEMBL9789988 | 0.79 | L3MBTL1 (0.41) | OPRL1ALDH1A1HPGDOPRM1OPRD1 | |
| SCHEMBL15967645 | 0.79 | — | — | |
| SCHEMBL6543647 | 0.77 | L3MBTL1 (0.42) | ALDH1A1HPGDAPOBEC3G | |
| SCHEMBL206897 | 0.76 | CYP2D6 (0.33) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL4159670 | 0.76 | CYP2D6 (0.33) | CYP2D6MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010066349-A1 | USE OF 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066354-A1 | USE OF 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066355-A1 | USE OF 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
| EP-2178899-A1 | 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-28 | — | — | EP | disclosed |
| EP-2170925-A2 | 17ß -CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-07 | — | — | EP | disclosed |
| EP-2167525-A2 | 17ß-CYANO-19-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008152112-A2 | 17ß-CYANO-19-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008151746-A2 | 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008151745-A1 | 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
| EP-0218541-A2 | 3-Vinyl and 3-ethinyl-beta-carboline derivatives, their preparation and their use as medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-04-15 | — | — | EP | disclosed |
| EP-0070804-B1 | FLUORALKOXY-AMINOPYRIMIDINES AND DITTO TRIAZINES | CIBA-GEIGY AG (CH) | 1987-04-08 | — | — | EP | disclosed |
| EP-0070804-A2 | Fluoralkoxy-aminopyrimidines and ditto triazines | CIBA-GEIGY AG (CH) | 1983-01-26 | — | — | EP | disclosed |
| EP-0025017-A1 | Polyazathia compounds, process for their preparation, pharmaceutical preparations containing such compounds and use of the latter | CIBA-GEIGY AG (CH) | 1981-03-11 | — | — | EP | disclosed |